Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 6/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689115 | 0.92 | KMT2A (0.51) | CMA1CTRB1KMT2AMEN1REN | |
| SCHEMBL8422163 | 0.88 | CTRB1 (0.53) | CMA1CTRB1KMT2AMEN1KLK7 | |
| SCHEMBL17002153 | 0.88 | CTRB1 (0.53) | CMA1CTRB1KMT2AMEN1KLK7 | |
| SCHEMBL30689122 | 0.88 | CTRB1 (0.48) | CMA1CTRB1KMT2AMEN1REN | |
| SCHEMBL30689131 | 0.87 | ITGB3 (0.54) | CMA1CTRB1RENELANEKLK7 | |
| SCHEMBL11598414 | 0.87 | CTRB1 (0.51) | CMA1CTRB1KMT2AMEN1KLK7 | |
| SCHEMBL30689107 | 0.87 | CTRB1 (0.51) | CMA1CTRB1KMT2AMEN1REN | |
| SCHEMBL30689119 | 0.87 | CTRB1 (0.56) | CMA1CTRB1KMT2AMEN1REN | |
| SCHEMBL30689109 | 0.87 | CMA1 (0.56) | CMA1CTRB1KMT2AMEN1ELANE | |
| SCHEMBL30689130 | 0.86 | CMA1 (0.58) | CMA1CTRB1KMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | CMA1 843/4885CTRB1 86/4885KMT2A 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.